Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
CADILA HEALTHCARE | FRESENIUS KABI ONCO. | CADILA HEALTHCARE/ FRESENIUS KABI ONCO. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 29.9 | 22.1 | 135.1% | View Chart |
P/BV | x | 4.8 | 3.1 | 154.7% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
FRESENIUS KABI ONCO. Mar-13 |
CADILA HEALTHCARE/ FRESENIUS KABI ONCO. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 176 | 200.2% | |
Low | Rs | 207 | 79 | 263.1% | |
Sales per share (Unadj.) | Rs | 139.2 | 37.7 | 369.4% | |
Earnings per share (Unadj.) | Rs | 11.8 | 5.1 | 231.0% | |
Cash flow per share (Unadj.) | Rs | 18.6 | 6.7 | 276.2% | |
Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
Dividend yield (eoy) | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.4 | 42.5 | 238.2% | |
Shares outstanding (eoy) | m | 1,023.74 | 158.23 | 647.0% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 3.4 | 59.4% | |
Avg P/E ratio | x | 23.7 | 25.0 | 95.1% | |
P/CF ratio (eoy) | x | 15.0 | 18.9 | 79.5% | |
Price / Book Value ratio | x | 2.8 | 3.0 | 92.2% | |
Dividend payout | % | 29.8 | 0 | - | |
Avg Mkt Cap | Rs m | 286,033 | 20,135 | 1,420.6% | |
No. of employees | `000 | 13.4 | 1.2 | 1,163.6% | |
Total wages/salary | Rs m | 24,145 | 703 | 3,433.6% | |
Avg. sales/employee | Rs Th | 10,632.7 | 5,176.2 | 205.4% | |
Avg. wages/employee | Rs Th | 1,801.2 | 610.4 | 295.1% | |
Avg. net profit/employee | Rs Th | 898.5 | 699.6 | 128.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 5,963 | 2,390.3% | |
Other income | Rs m | 1,139 | 18 | 6,327.8% | |
Total revenues | Rs m | 143,670 | 5,981 | 2,402.1% | |
Gross profit | Rs m | 24,198 | 1,430 | 1,692.0% | |
Depreciation | Rs m | 6,965 | 258 | 2,700.7% | |
Interest | Rs m | 3,418 | -26 | -13,146.2% | |
Profit before tax | Rs m | 14,954 | 1,216 | 1,229.6% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -68 | 0.0% | |
Tax | Rs m | 3,198 | 342 | 934.5% | |
Profit after tax | Rs m | 12,044 | 806 | 1,494.5% | |
Gross profit margin | % | 17.0 | 24.0 | 70.8% | |
Effective tax rate | % | 21.4 | 28.1 | 76.0% | |
Net profit margin | % | 8.5 | 13.5 | 62.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 5,102 | 1,708.4% | |
Current liabilities | Rs m | 82,694 | 2,385 | 3,466.7% | |
Net working cap to sales | % | 3.1 | 45.6 | 6.9% | |
Current ratio | x | 1.1 | 2.1 | 49.3% | |
Inventory Days | Days | 71 | 150 | 47.6% | |
Debtors Days | Days | 94 | 113 | 82.8% | |
Net fixed assets | Rs m | 133,236 | 5,148 | 2,588.1% | |
Share capital | Rs m | 1,024 | 158 | 647.3% | |
"Free" reserves | Rs m | 102,733 | 6,556 | 1,567.1% | |
Net worth | Rs m | 103,757 | 6,732 | 1,541.3% | |
Long term debt | Rs m | 32,146 | 952 | 3,376.0% | |
Total assets | Rs m | 236,866 | 10,388 | 2,280.2% | |
Interest coverage | x | 5.4 | -45.8 | -11.7% | |
Debt to equity ratio | x | 0.3 | 0.1 | 219.0% | |
Sales to assets ratio | x | 0.6 | 0.6 | 104.8% | |
Return on assets | % | 6.5 | 7.5 | 86.9% | |
Return on equity | % | 11.6 | 12.0 | 97.0% | |
Return on capital | % | 13.7 | 14.6 | 94.0% | |
Exports to sales | % | 0 | 74.5 | 0.0% | |
Imports to sales | % | 0 | 24.8 | 0.0% | |
Exports (fob) | Rs m | NA | 4,441 | 0.0% | |
Imports (cif) | Rs m | NA | 1,477 | 0.0% | |
Fx inflow | Rs m | 52,752 | 5,298 | 995.8% | |
Fx outflow | Rs m | 14,504 | 1,772 | 818.4% | |
Net fx | Rs m | 38,248 | 3,525 | 1,084.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 1,274 | 1,966.4% | |
From Investments | Rs m | -10,123 | -1,204 | 840.6% | |
From Financial Activity | Rs m | -10,942 | -196 | 5,579.8% | |
Net Cashflow | Rs m | 3,989 | -126 | -3,158.4% |
Indian Promoters | % | 74.8 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 81.0 | - | |
Indian inst/Mut Fund | % | 8.3 | 0.3 | 2,766.7% | |
FIIs | % | 5.9 | 9.6 | 61.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 11.0 | 9.1 | 120.9% | |
Shareholders | 44,069 | 42,599 | 103.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: SANOFI INDIA ABBOTT INDIA STRIDES PHARMA SCIENCE CIPLA TORRENT PHARMA
Compare CADILA HEALTHCARE With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More